Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

NCT03066206 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

93

Enrollment

OTHER

Sponsor class

Stopped \<75% participation

Conditions

EGFR Exon 20 Mutation
ERBB2 Gene Mutation
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Non-Small Cell Lung Cancer AJCC v7

Interventions

DRUG: Poziotinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]